{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:54:33Z","timestamp":1788346473548,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.transci.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T08:05:45Z","timestamp":1519113945000},"page":"4-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The management of hyperleukocytosis in 2017: Do we still need leukapheresis?"],"prefix":"10.1016","volume":"57","author":[{"given":"Serdal","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2018.02.006_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjh.13189","article-title":"Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis","volume":"168","author":"Daver","year":"2015","journal-title":"J Haematol"},{"issue":"1","key":"10.1016\/j.transci.2018.02.006_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00321058","article-title":"Leucostasis, an underestimated cause of death in leukaemia","volume":"56","author":"van Buchem","year":"1988","journal-title":"Blut"},{"issue":"1","key":"10.1016\/j.transci.2018.02.006_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.2830400106","article-title":"Pulmonary leukostasis without hyperleukocytosis: a clinicopathologic study of 16 cases","volume":"40","author":"Soares","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2018.02.006_bib0020","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.23581","article-title":"Clinical and biologic features and treatment outcome of children with newly diagnosed acutemyeloid leukemia and hyperleukocytosis","volume":"113","author":"Inaba","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2018.02.006_bib0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1172\/JCI116978","article-title":"Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes","volume":"93","author":"Sorensen","year":"1994","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.transci.2018.02.006_bib0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0889-8588(18)30262-4","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"7","author":"Lestingi","year":"1993","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.transci.2018.02.006_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190009053534","article-title":"Hyperleukocytic leukemias: a review of pathophysiology, clinical presentation and management","volume":"39","author":"Porcu","year":"2000","journal-title":"Leuk Lymphom"},{"key":"10.1016\/j.transci.2018.02.006_bib0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2292","article-title":"Leukostasis in adult acute hyperleukocytic leukemia: a clinician\u2019s digest","volume":"34","author":"Ali","year":"2016","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.transci.2018.02.006_bib0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V60.2.279.bloodjournal602279","article-title":"Hyperleukocytic leukemias. rheological, clinical, and therapeutic considerations","volume":"60","author":"Lichtman","year":"1982","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.transci.2018.02.006_bib0050","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","article-title":"Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination","volume":"97","author":"Stucki","year":"2001","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.transci.2018.02.006_bib0055","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1200\/JCO.2011.36.2756","article-title":"Reversal of leukostasis-related pulmonary distress syndrome after leukapheresis and low-dose chemotherapy in acute myeloid leukemia","volume":"29","author":"Piro","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2018.02.006_bib0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","article-title":"Hyperleukocytosis, leukostasis and leukapheresis: practice management","volume":"26","author":"Ganzel","year":"2012","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.transci.2018.02.006_bib0065","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1200\/JCO.1989.7.10.1528","article-title":"A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings","volume":"7","author":"Karesh","year":"1989","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.transci.2018.02.006_bib0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005792-197411000-00006","article-title":"Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia","volume":"53","author":"McKee","year":"1974","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.transci.2018.02.006_bib0075","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.1.6121.1169","article-title":"Leukostasis associated with blood transfusion in acute myeloid leukaemia","volume":"1","author":"Harris","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.transci.2018.02.006_bib0080","first-page":"1007","article-title":"Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts","volume":"65","author":"Vaughan","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.transci.2018.02.006_bib0085","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"R\u00f6llig","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.transci.2018.02.006_bib0090","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinte.1977.03630210112032","article-title":"Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia","volume":"137","author":"Grund","year":"1977","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.transci.2018.02.006_bib0095","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/jcb.24394","article-title":"Annexin A1 mediates the anti-adhesive effects of the dexamethasone-treated promyelocytic leukemic cells","volume":"114","author":"Tsai","year":"2013","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.transci.2018.02.006_bib0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1600-0609.2005.00421.x","article-title":"Grading of symptoms in hyperleukocytic leukemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome","volume":"74","author":"Novotny","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2018.02.006_bib0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.21418","article-title":"Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis","volume":"84","author":"Piccirillo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2018.02.006_bib0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10428190109097677","article-title":"Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival","volume":"42","author":"Giles","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2018.02.006_bib0115","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1537-2995.2007.01406.x","article-title":"Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis","volume":"47","author":"Bug","year":"2007","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.transci.2018.02.006_bib0120","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ajh.20939","article-title":"Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage","volume":"82","author":"Chang","year":"2007","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.transci.2018.02.006_bib0125","doi-asserted-by":"crossref","first-page":"e95062","DOI":"10.1371\/journal.pone.0095062","article-title":"The role of therapeutic leukapheresis in hyperleukocytic AML","volume":"9","author":"Pastore","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2018.02.006_bib0130","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/pbc.26056","article-title":"The role of leukapheresis in the current management of hyperleukocytosis in newly diagnosed childhood acute lymphoblastic leukemia","volume":"63","author":"Nguyen","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.transci.2018.02.006_bib0135","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jfma.2014.01.006","article-title":"Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis","volume":"113","author":"Chen","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.transci.2018.02.006_bib0140","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2014.01.004","article-title":"Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis","volume":"38","author":"Oberoi","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.transci.2018.02.006_bib0145","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ajh.21547","article-title":"Management of hematological malignancies during pregnancy","volume":"84","author":"Rizack","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2018.02.006_bib0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hemonc.2014.03.001","article-title":"Leukemia during pregnancy: long term follow up of 32 cases from a single institution","volume":"7","author":"Saleh","year":"2014","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.transci.2018.02.006_bib0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1098-1101(1999)14:1<42::AID-JCA8>3.0.CO;2-2","article-title":"Management of chronic myeloid leukemia during pregnancy with leukapheresis","volume":"14","author":"Strobl","year":"1999","journal-title":"J Clin Apher"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218300405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218300405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T05:38:55Z","timestamp":1570772335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050218300405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1473050218300405"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2018.02.006","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of hyperleukocytosis in 2017: Do we still need leukapheresis?","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}